John Dunlop, Karen L. Marquis, HK Lim, Louis Leung, John Kao, Cynthia Cheesman, Sharon Rosenzweig-Lipson
{"title":"Pharmacological Profile of the 5-HT2C Receptor Agonist WAY-163909; Therapeutic Potential in Multiple Indications","authors":"John Dunlop, Karen L. Marquis, HK Lim, Louis Leung, John Kao, Cynthia Cheesman, Sharon Rosenzweig-Lipson","doi":"10.1111/j.1527-3458.2006.00167.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The 5-HT<sub>2C</sub> receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7b<i>R</i>,10a<i>R</i>)-1,2,3,4,8,9,10,10a-octahydro-7b<i>H</i>-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT<sub>2C</sub> receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.</p>\n </div>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":"12 3-4","pages":"167-177"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.2006.00167.x","citationCount":"73","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2006.00167.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 73
Abstract
The 5-HT2C receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT2C receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
